Xvivo Perfusion AB (Xvivo Perfusion AB) Interest Expense : $-0.39 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Xvivo Perfusion AB's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.39 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Xvivo Perfusion AB's Operating Income for the three months ended in Mar. 2024 was $ 1.82 Mil. Xvivo Perfusion AB's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Xvivo Perfusion AB's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Xvivo Perfusion AB Interest Expense Historical Data

The historical data trend for Xvivo Perfusion AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Interest Expense Chart

Xvivo Perfusion AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.03

-0.04

-0.03

-0.06

-0.12

Xvivo Perfusion AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-0.39	-	-

Xvivo Perfusion AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39 Mil.

Xvivo Perfusion AB (OTCPK:XVIPF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Xvivo Perfusion AB's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $1.82 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $1.91 Mil.

Xvivo Perfusion AB's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Xvivo Perfusion AB's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

XVIVO:Sweden 3XV:Germany

Address

Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14

Website

https://www.xvivoperfusion.com

Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.